A unique physiological operating mode

Resulting from years of research and development

The LTV prosthetic heart valve is the result of years of research in collaboration with world leaders in aeronautic technologies, medicine, and science:

    1. Fluid mechanics (initial development with Dassault-Aviation37).
    2. Advanced biomaterials.
    3. High-precision Swiss manufacturing.
    4. Prominent academic laboratories with expertise in aerodynamics and Computational Fluid Dynamics.
    5. Bio-molecular experts in flow-induced platelet activation and thrombosis.

 


Addressing a longstanding patient need and a major scientific issue

Because of an innovative anatomic tri-leaflet design with a physiological operating mode and composed of high-performance biocompatible materials, the Lapeyre-Triflo valve may be the first prosthetic heart valve resistant to both thrombosis and structural failure.

Unique properties combined in a single valve:

  • Resistant to thrombosis  (free of lifelong anticoagulation therapy).  Read more...

    • During the last few years, major basic science discoveries have been made, suggesting that the primary cause of thrombo-embolic complications in existing bi-leaflet mechanical heart valves (introduced in the 1970s) is design related. Advanced experimental and numerical tools in fluid mechanics have detected very high fluid forces during the reverse flow in existing mechanical valves17. At the same time, breakthroughs in molecular biology of the haemostatic function10 brought evidence that non-physiological fluid forces in the blood elicit an explosive coagulation response.
    • As a result of its unique physiological operating mode (early and soft closing during the flow deceleration, no area of slow flow), the LTV valve is expected to prevent the flow-induced mechanisms leading to thromboembolism observed on existing mechanical valves.
    • Experimental, numerical and animal testing demonstrates that the LTV valve  physiologically operates like a native human heart valve: it opens and closes like a tissue valve, does not produce high velocity backflow jets, does not elicit an haemostatic response and thus may function without warfarin anticoagulation therapy.
  • Resistant to structural failure  (one valve for life).  Read more...

    • Unlike tissue valves, which have limited durability, especially with young patients, the LTV prosthetic heart valve is structurally designed to last a lifetime for patients of any age, thereby avoiding the risk of a re-operation.
    • The LTV valve is made of high-performance biocompatible materials with outstanding wear and fatigue resistance able to withstand the high cardiac cycles (valves open and close about 100,000 times a dayi.e. more than 36 million times a year).
    • Unlike existing mechanical valves, the LTV valve no-hinge design reduces friction and wear to virtually zero while preventing leaflet lockup or escape.  

Preclinical evidence


Offering other substantial benefits

  • Outstanding hemodynamics.  Read more...

    • With its central flow tri-leaflet design, the LTV valve demonstrates superior hemodynamic performances. Its unique design permits unimpeded leaflet opening and optimal blood flow with low shear stress and turbulence through the pivot areas.
  • Remarkably noiseless.  Read more...

    • Due to its specific design, the LTV valve functions like a native valve and closes smoothly and silently at zero flow, eliminated the “click” perceived by some patients with current mechanical valves. In addition, the leaflets are made of a silent new high-performance polymer that replaces traditional carbon ceramic material.

  • Ease of implantation.  Read more...

    • The LTV valve is implanted through well established open-heart surgical procedures performed with excellent outcomes for more than 50 years. With the recent advances in conventional surgery, the valve may also be implanted through minimally invasive heart valve surgery
  • Designed for a wide range of sizes (including small ones for children) for both aortic and mitral positions. Read more...

    • The LTV valve will be manufactured in a wide range of sizes without sacrificing hemodynamic efficiency (aortic valves from 16 to 27 mm / mitral valves from 25 to 33 mm).

    • The valve will be suitable for all operable patients, including children. It is worth noting that in the United States the Food and Drug Administration (FDA) is very sensitive to the current lack of devices for children and has launched a grant program to address this need.

 

 

Discover which patients may benefit from the LTV valve